<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tocilizumab</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06273</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. <span class="caps">FDA</span> approved on January 8, 2010.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>6428</sub>H<sub>9976</sub>N<sub>1720</sub>O<sub>2018</sub>S<sub>42</sub></td></tr><tr><th>Protein average weight</th><td>148 kDa </td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Atlizumab</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>MRA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>RoActemra&#174;</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Actemra</td><td>Genentech</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>375823-41-9</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.</td></tr><tr><th>Pharmacodynamics</th><td>A decrease in C-reactive protein (CRP) was noted as early as week 2. Changes in pharmacodynamic parameters were observed (i.e., decreases in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A and increases in hemoglobin) with both doses, however the greatest improvements were observed with 8 mg per kg tocilizumab. Similar pharmacodynamic changes were also observed in active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis patients. </td></tr><tr><th>Mechanism of action</th><td>Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.</td></tr><tr><th>Absorption</th><td>When 4 mg/kg of tocilizumab was given every 4 weeks to RA patients, the pharmacokinetic parameters at steady state are as follows: 
AUC = 13000 &#177; 5800 mcg&#8729;h/mL;
Cmax = 88.3 &#177; 41.4 mcg/mL. 
Tocilizumab accumulates following repeated doses. Furthermore, an increased body weight may increase plasma levels of tocilizumab. 

When a dose of 8 mg/kg of tocilizumab is given to PJIA patients, the pharmacokinetic parameters are as follows:
AUC =  29500 &#177; 8660 mcg&#8729;h/mL;
Cmax = 182 &#177; 37 mcg/mL. 

When a dose of 8 mg/kg of tocilizumab is given to SJIA patients, the pharmacokinetic parameters are as follows:
AUC = 32200 &#177; 9960 mcg&#8729;h/mL;
Cmax = 245 &#177; 57.2 mcg/mL. 
</td></tr><tr><th>Volume of distribution</th><td><p>In rheumatoid arthritis patients the central volume of distribution was 3.5 L and the peripheral volume of distribution was 2.9 L, resulting in a volume of distribution at steady state of 6.4 L.</p>
<p>In pediatric patients with <span class="caps">PJIA</span>, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.</p>
<p>In pediatric patients with <span class="caps">SJIA</span>, the central volume of distribution was 0.94 L, the peripheral volume of distribution was 1.60 L resulting in a volume of distribution at steady state of 2.54 L.</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Following intravenous dosing, tocilizumab undergoes biphasic elimination from the circulation.</td></tr><tr><th>Half life</th><td>The half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.</td></tr><tr><th>Clearance</th><td><p>The clearance of tocilizumab decreases with increasing dose. At the 10 mg/kg single dose in RA patients, mean clearance was 0.29 &#177; 0.10 mL/hr/kg. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear clearance and the nonlinear clearance. At low concentrations, concentration-dependent nonlinear clearance is dominant. At high concentrations, linear clearance dominates. The estimated linear clearances for specific patient populations are as follows:<br>
RA = 12.5 mL/h;<br>
<span class="caps">PJIA</span>, pediatric patients = 5.8 mL/h;<br>
<span class="caps">SJIA</span>, pediatric patients = 7.1 mL/h.</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution, concentrate</td><td>Intravenous</td><td>80 mg/4 mL; 200 mg/10 mL; 400 mg/20 mL</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>Canada</td><td>2201781</td><td>2010-01-12</td><td>2015-06-07</td></tr><tr><td>Canada</td><td>1341152</td><td>2000-12-12</td><td>2017-12-12</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15934843">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA165292659" target="_blank">PA165292659 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/actemra-drug.htm" target="_blank">http://www.rxlist.com/actemra-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/international/tocilizumab.html" target="_blank">http://www.drugs.com/international/tocilizumab.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Tocilizumab" target="_blank">Tocilizumab <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L04AC07<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L04#L04">L04 &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04A#L04A">L04A &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04AC#L04AC">L04AC &#8212; Interleukin inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>92:36 </li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB06273.pdf?1371623110">show</a>(623 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB06273.pdf?1371623110">show</a>(482 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Dextromethorphan is a CYP2D6 and CYP3A4 substrate. Exposure of dextromethorphan decreases following administration of tocilizumab.</td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination due to the enhanced immunosuppression by TNF blockers.
</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab.. </td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab. </td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination due to the potential increase in tofacitinib related adverse effects.
</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>